dc.contributor.author
Vitulo, Patrizio
dc.contributor.author
Piccari, Lucilla
dc.contributor.author
Wort, Stephen John
dc.contributor.author
Shlobin, Oksana A.
dc.contributor.author
Kovacs, Gabor
dc.contributor.author
Vizza, Carmine Dario
dc.contributor.author
Hassoun, Paul
dc.contributor.author
Olschewski, Horst
dc.contributor.author
Girgis, Reda E.
dc.contributor.author
Nikkho, Sylvia M.
dc.contributor.author
Nathan, Steven D.
dc.date.accessioned
2026-02-18T05:18:07Z
dc.date.available
2026-02-18T05:18:07Z
dc.date.issued
2026-02-17T16:31:49Z
dc.date.issued
2026-02-17T16:31:49Z
dc.date.issued
2026-02-17T16:31:49Z
dc.identifier
Vitulo P, Piccari L, Wort SJ, Shlobin OA, Kovacs G, Vizza CD, Hassoun PM, Olschewski H, Girgis RE, Nikkho SM, Nathan SD. Screening and diagnosis of pulmonary hypertension associated with chronic lung disease (PH-CLD): a consensus statement from the pulmonary vascular research institute's innovative drug development initiative-group 3 pulmonary hypertension. Pulm Circ. 2024 Dec 10;14(4):e70005. DOI: 10.1002/pul2.70005
dc.identifier
https://hdl.handle.net/10230/72577
dc.identifier
http://dx.doi.org/10.1002/pul2.70005
dc.identifier.uri
http://hdl.handle.net/10230/72577
dc.description.abstract
Pulmonary hypertension (PH) is a frequent complication of chronic lung disease (CLD). However, PH is difficult to diagnose early since accompanying symptoms overlap and are similar to those of the underlying CLD. In most cases the PH is mild to moderate and therefore physical signs may be absent or subtle. This consensus paper provides insight into the clues that might suggest the presence of occult PH in patients with CLD. An overview of current diagnostic tools and emerging diagnostic technologies is provided as well as guidance for the work-up and diagnosis of PH in patients with CLD.
dc.format
application/pdf
dc.format
application/pdf
dc.relation
Pulmonary Circulation. 2024 Dec 10;14(4):e70005
dc.rights
© 2024 The Author(s). Pulmonary Circulation published by John Wiley & Sons Ltd on behalf of Pulmonary Vascular Research Institute. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
dc.rights
http://creativecommons.org/licenses/by-nc/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Chronic lung disease
dc.subject
Pulmonary hypertension
dc.title
Screening and diagnosis of pulmonary hypertension associated with chronic lung disease (PH-CLD): a consensus statement from the pulmonary vascular research institute's innovative drug development initiative-group 3 pulmonary hypertension.
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion